Nextgen Biomed Ltd
Символ: NXGN.TA
TLV
101.8
ILAПазарна цена днес
-106.3909
Съотношение P/E
0.0000
Коефициент PEG
7.56M
MRK Cap
- 0.00%
Доходност на DIV
Nextgen Biomed Ltd (NXGN-TA) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 26.14 | 5.2 | 12 | 5.7 | |||||||||
balance-sheet.row.short-term-investments | 0.01 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-current-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-current-assets | 26.85 | 5.3 | 12.3 | 5.9 | |||||||||
balance-sheet.row.property-plant-equipment-net | 0.02 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17.74 | 1.6 | 7.3 | 0 | |||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 28.81 | 8.1 | 4.1 | 2.4 | |||||||||
balance-sheet.row.total-non-current-assets | 46.57 | 9.6 | 11.4 | 2.4 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 73.42 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.account-payables | 0.52 | 0.2 | 0.1 | 0.1 | |||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 3.88 | 1.1 | 0.6 | 1.4 | |||||||||
balance-sheet.row.total-non-current-liabilities | 6.95 | 1.4 | 2.1 | 0 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-liab | 11.35 | 2.6 | 2.9 | 1.5 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.retained-earnings | -194.04 | -51.9 | -43.3 | -40.7 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 256.54 | 64.2 | 64.1 | 47.7 | |||||||||
balance-sheet.row.total-stockholders-equity | 62.5 | 12.4 | 20.8 | 7 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 73.42 | 14.9 | 23.6 | 8.3 | |||||||||
balance-sheet.row.minority-interest | -0.44 | -0.1 | -0.1 | -0.1 | |||||||||
balance-sheet.row.total-equity | 62.17 | 12.3 | 20.7 | 6.9 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 73.42 | - | - | - | |||||||||
Total Investments | 0.01 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.net-debt | -26.13 | -5.2 | -12 | -5.7 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -6.91 | -8.6 | -2.5 | -1.3 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.01 | 0 | 0 | 0 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 5 | -0.1 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0.2 | 0.2 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0.18 | 0.7 | 0 | -0.2 | ||||||||||
cash-flows.row.account-receivables | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 0.06 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0.08 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 5.28 | 0 | -0.1 | 0 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -1.45 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -0.5 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -2 | -1.9 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4 | -2.5 | -2.4 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-issued | 0.09 | 0 | 11.4 | 7 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0 | 0.7 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0.09 | 0 | 11.4 | 7.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -1.36 | -6.7 | 6.3 | 3.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 10.48 | 5.2 | 11.9 | 5.7 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 11.84 | 12 | 5.7 | 1.9 | ||||||||||
cash-flows.row.operating-cash-flow | -1.45 | -2.8 | -2.7 | -1.5 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -1.45 | -2.8 | -3.2 | -1.5 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.01 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | -0.01 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0.29 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.operating-expenses | 1.86 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 1.87 | 3.6 | 2.8 | 1.3 | ||||||||||
income-statement-row.row.interest-income | 0.66 | 0 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -5.05 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | -5 | 0 | 0 | ||||||||||
income-statement-row.row.total-operating-expenses | -5.05 | 0.7 | 0.3 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0 | 0 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.01 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.ebitda-caps | -1.86 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -1.87 | -9.3 | -2.8 | -1.3 | ||||||||||
income-statement-row.row.income-before-tax | -6.92 | -8.6 | -2.6 | -1.3 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 0.8 | 0.3 | 0 | ||||||||||
income-statement-row.row.net-income | -6.91 | -8.6 | -2.5 | -1.3 |
Често задавани въпроси
Какво е Nextgen Biomed Ltd (NXGN.TA) общи активи?
Nextgen Biomed Ltd (NXGN.TA) общите активи са 14888000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са N/A.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.200.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.200.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.000.
Какъв е общият приход на предприятието?
Общият приход е 0.000.
Каква е Nextgen Biomed Ltd (NXGN.TA) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -8572000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 0.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 3581000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 2328000.000.